title: [Recombinant factor VII activated in non-hemophiliac patients with acute severe hemorrhage in the intensive care unit].
abstract: BACKGROUND
  Severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. Recombinant Factor VIla (rFVlla) constitutes a new therapeutic alternative.
  
  
  OBJECTIVE
  Analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rFVlla.
  
  
  METHODS
  Ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rFVIIa. We used a t test for statistic analyses. Significance was set at p < 0.001.
  
  
  RESULTS
  Among patients treated with rFVlla, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). Coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001).
  
  
  CONCLUSIONS
  rFVIIa is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.
authors.affiliation: Academia Nacional de Medicina, Academia Mexicana de Cirugía, México D. F., México. sencocapcmamail@medinet.net.mx
authors.forename: Raúl
authors.initials: R
authors.lastname: Carrillo-Esper
authors.forename: Martín de Jesús
authors.initials: Mde J
authors.lastname: Sánchez-Zúñiga
authors.forename: Sandra
authors.initials: S
authors.lastname: Elizondo-Argueta
authors.forename: Porfirio
authors.initials: P
authors.lastname: Visoso-Palacios
authors.forename: Jorge Raúl
authors.initials: JR
authors.lastname: Carrillo-Córdova
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001780:Blood Coagulation Tests; D016913:Blood Component Transfusion; D016638:Critical Illness; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa